UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
____________________
Date of report (Date of earliest event reported): November 7, 2019
Amyris, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-34885 | 55-0856151 |
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| 5885 Hollis Street, Suite 100, Emeryville, CA | 94608 | ||
| (Address of principal executive offices) | (Zip Code) |
| (510) 450-0761 | ||
| (Registrant’s telephone number, including area code) |
| (Former name or former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2 below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, $0.0001 par value per share | AMRS | The Nasdaq Stock Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 | Results of Operations and Financial Condition. |
On November 7, 2019, Amyris, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal quarter ended September 30, 2019. A copy of this press release, entitled “Amyris Continues to Deliver Strong Revenue Growth,” is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
The following exhibit is furnished herewith:
| Exhibit Number | Description |
| 99.1 | Press release, issued November 7, 2019, entitled “Amyris Continues to Deliver Strong Revenue Growth” |
The information in this report, including the exhibit hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AMYRIS, INC. | |||
| Date: November 7, 2019 | By: | /s/ Jonathan Wolter | |
| Jonathan Wolter | |||
| Interim Chief Financial Officer | |||
Exhibit 99.1
Amyris Continues to Deliver Strong Revenue Growth
| · | Q3 2019 GAAP revenue of $35.0 million, up 144% over GAAP revenue of $14.3 million for Q3 2018. |
| · | Year to date GAAP revenue of $112.0 million, up 137% over $47.2 million for the prior year period |
| · | Product revenue of $19.7 million is more than double Q3 of 2018 |
| · | CVI Heights convertible debt with clear resolution |
EMERYVILLE, Calif. (November 7, 2019) -- Amyris, Inc. (Nasdaq:AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced preliminary unaudited financial results for the third quarter ended September 30, 2019.
“We are pleased with our Q3 results,” said John Melo, President and CEO of Amyris. “We are continuing to double our product revenue year over year and we are on track to exceed our $150 million in revenue guidance for 2019. While capital constraints proved challenging, we were able to carefully manage the business to deliver on significant demand across most of our core products. These capital constraints should be lessened as a result of having achieved SEC filing and Nasdaq compliance, resolving our CVI Heights debt, expanding our gross margin, and continuing the revenue growth of our business over the coming quarters.”
Continued Melo, “Our Biossance brand is redefining consumer expectations for high performing, clean and sustainable skin care. Purecane™ sweetener and Pipette™ baby care are experiencing excellent early engagement with consumers and the early consumer product ratings for both of these new brands are outstanding. These brands provide clean, sustainable and highly effective products with ingredients produced by Amyris. Products such as these that deliver the best performance in their respective categories is where we excel and where we are capturing a market leadership position. Our fourth quarter has started strong and we are on track for a great finish to 2019.
“Our cannabinoids development program is advancing at
a much better rate than we expected, and we will have product available for sampling and early formulation development early in
2020. We remain confident in our ability to commercially launch these cannabinoids in 2020, assuming regulatory conditions have
been met. Upon commercial scale, this program should generate significant product revenue as well as royalties to Amyris.”
Key Highlights
Other operating and development highlights included:
| · | Successfully launched Pipette™ brand, the new standard in clean baby care with better-performing, safer products for moms and babies using ingredients from the purest sources. |
| · | Biossance clean skin care brand has entered the Australian and New Zealand markets as global expansion continues. Biossance revenue growth is escalating based on growing geographic footprint and number of Sephora stores (now 219 out of 480 total North American stores carrying the full end cap of all product SKUs at quarter end). More recently, Sephora introduced Biossance to the South Korea and Thailand markets furthering the brand’s continued geographic expansion and growth opportunity. |
| · | Cannabinoids development progressing better than expected with CBD ahead of target delivery with anticipated commercialization of both CBD and a second unnamed (due to partner’s competitive considerations) cannabinoid molecule, subject to regulatory clearance, available for commercialization in 2020. |
| · | Significantly expanded collaboration agreement with Yifan of China. |
| · | Closed on financings to support working capital and revenue growth as well as agreement to resolve the CVI Heights unsecured convertible senior notes debt. |
Financial Performance (preliminary unaudited)
Third Quarter 2019
| · | GAAP revenue for the third quarter of 2019 was $35.0 million, compared with $14.3 million for the third quarter of 2018. Renewable products revenue (including royalties connected to renewable products we produced and shipped) for the quarter was $19.7 million compared with $9.8 million for the same period a year ago. Grants and collaborations revenue was $15.3 million for the third quarter of 2019 compared with $4.5 million for the year-ago period. |
| · | Sales, general and administrative expenses were $33.3 million for the third quarter of 2019 compared with $27.2 million for year-ago period, primarily reflecting Biossance growth and an increase in headcount as well as certain one-time expenses. Research and development expenses of $19.0 million for the quarter were up from $16.4 million for the third quarter of 2018 due to increased R&D costs for product development connected to the increase in collaboration revenue over 2018. |
| · | GAAP net loss attributable to Amyris common stockholders for the third quarter of 2019 was $53.2 million, or $0.51 per basic and diluted share, compared with a GAAP net loss attributable to Amyris common stockholders for the third quarter of 2018 of $76.8 million, or $1.26 per basic and diluted share. |
| · | Non-GAAP net loss for the third quarter of 2019 was $46.4 million, or $0.45 per basic share. This compared with a non-GAAP net loss of $46.7 million, or $0.77 per basic share for the third quarter of 2018. |
Nine Months Ended September 30, 2019
| · | GAAP revenue for the first nine months ended September 30, 2019 was $112.0 million, compared with $47.2 million for the same period of 2018. Product revenue (including royalties connected to renewable products we produced and shipped) more than doubled for the 2019 period versus the prior year period. |
| · | GAAP net loss attributable to Amyris common stockholders for first nine months of 2019 was $188.0 million, or $2.06 per basic and diluted share. This compared to a net loss of $175.7 million, or $3.15 per basic and diluted share for the first nine months of 2018. |
| · | Non-GAAP net loss for the first nine months of 2019, excluding the non-cash items mentioned, was $119.4 million, or $1.31 per basic share, compared to a non-GAAP net loss for the first nine months of 2018 of $114.3 million, or $2.05 per basic share. |
FINANCIAL RESULTS AND NON-GAAP INFORMATION
To supplement our financial results and guidance presented on a GAAP basis, we use non-GAAP measures that we believe are helpful in understanding our results. These non-GAAP measures are among the factors management uses in planning and forecasting future periods. These non-GAAP financial measures also facilitate management’s internal comparisons to Amyris’s historical performance as well as comparisons to the operating results of other companies. Management believes these non-GAAP financial measures are useful to investors because they allow for greater transparency into the indicators used by management to understand, manage, and evaluate our business and make operating decisions. Our non-GAAP financial measures include the following:
Non-GAAP net income (loss) is calculated as GAAP net income/loss excluding impairment, stock-based compensation expense, gain on divestitures, gains and losses from changes in the fair value of derivatives, debt extinguishment costs, and depreciation and amortization.
Non-GAAP financial information is not prepared under a comprehensive set of accounting rules, and therefore, should only be read in conjunction with financial information reported under U.S. GAAP in order to understand Amyris’s operating performance. A reconciliation of the non-GAAP financial measures presented in this release, including non-GAAP net income (loss), to the most directly comparable GAAP financial measure, is provided in the tables attached to this press release.
QUARTERLY CONFERENCE CALL TODAY
Amyris will discuss these results and provide a business update in a conference call scheduled for 4:30 p.m. ET (1:30 p.m. PT) today. Investors may access the call by dialing (877) 870-4263. Participants should ask to be joined to the Amyris, Inc. call.
A live audio webcast of this conference call and accompanying presentation is also available by visiting the investor relations section of the company's website at http://investors.amyris.com. A replay of the webcast will be available at the investor relations section of the company's website approximately two hours after the conclusion of the call.
About Amyris
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise™ products and services across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com.
Forward-Looking Statements
This release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events, such as expected revenue, gross margin and revenue and gross margin growth for 2019 and beyond, the anticipated development and commercialization of the company’s cannabinoid products, including the timing thereof and potential product revenue and royalties related thereto, and expected growth of the company’s Biossance business, including revenue growth and geographic expansion. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to Amyris's liquidity and ability to fund operating and capital expenses, risks related to potential delays or failures in development, production and commercialization of products, risks related to Amyris's reliance on third parties, and other risks detailed from time to time in filings Amyris makes with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Amyris disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events, or otherwise.
Amyris, the Amyris logo, Biossance, Pipette, Purecane, and No Compromise are trademarks or registered trademarks of Amyris, Inc. in the U.S. and/or other countries. All other trademarks are the property of their respective owners.
Contact:
Peter DeNardo
Director, Investor Relations and Corporate Communications
Amyris, Inc.
+1 (510) 740-7481
investor@amyris.com
-Financial Tables Attached-
Amyris, Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
| (In thousands, except shares and per share amounts) | September 30, 2019 | December 31, 2018 | ||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 1,632 | $ | 45,353 | ||||
| Restricted cash | 476 | 741 | ||||||
| Accounts receivable, net of allowance of $116 and $642 | 17,072 | 16,003 | ||||||
| Accounts receivable - related party, net of allowance of $21 and $0 | 3,692 | 1,349 | ||||||
| Contract assets | 2,567 | - | ||||||
| Accounts receivable, unbilled - related party | - | 8,021 | ||||||
| Inventories | 15,944 | 9,693 | ||||||
| Deferred cost of products sold - related party | 968 | 489 | ||||||
| Prepaid expenses and other current assets | 12,849 | 10,566 | ||||||
| Total current assets | 55,200 | 92,215 | ||||||
| Property, plant and equipment, net | 24,436 | 19,756 | ||||||
| Accounts receivable, unbilled, noncurrent - related party | 1,203 | 1,203 | ||||||
| Deferred cost of products sold, noncurrent - related party | 15,894 | 2,828 | ||||||
| Restricted cash, noncurrent | 960 | 960 | ||||||
| Recoverable taxes from Brazilian government entities | 2,866 | 3,005 | ||||||
| Right-of-use assets under leases | 21,936 | - | ||||||
| Other assets | 5,620 | 7,958 | ||||||
| Total assets | $ | 128,115 | $ | 127,925 | ||||
| Liabilities, Mezzanine Equity and Stockholders' Deficit | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 24,925 | $ | 26,844 | ||||
| Accrued and other current liabilities | 37,886 | 28,979 | ||||||
| Lease liabilities | 7,973 | - | ||||||
| Contract liabilities | 4,737 | 8,236 | ||||||
| Debt, current portion (instrument measured at fair value $63,152 and $57,918, respectively) | 65,495 | 124,010 | ||||||
| Related party debt, current portion | 13,221 | 23,667 | ||||||
| Total current liabilities | 154,237 | 211,736 | ||||||
| Long-term debt, net of current portion | 20,045 | 43,331 | ||||||
| Related party debt, net of current portion | 105,482 | 18,689 | ||||||
| Lease liabilities, net of current portion | 15,472 | - | ||||||
| Derivative liabilities | 9,357 | 42,796 | ||||||
| Other noncurrent liabilities | 26,801 | 23,192 | ||||||
| Total liabilities | 331,394 | 339,744 | ||||||
| Commitments and contingencies | ||||||||
| Mezzanine equity: | ||||||||
| Contingently redeemable common stock | 5,000 | 5,000 | ||||||
| Stockholders’ deficit: | ||||||||
| Preferred stock - $0.0001 par value, 5,000,000 shares authorized as of September 30, 2019 and December 31, 2018, and 14,656 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively | - | - | ||||||
| Common stock - $0.0001 par value, 250,000,000 shares authorized as of September 30, 2019 and December 31, 2018; 103,400,207 and 76,564,829 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively | 10 | 8 | ||||||
| Additional paid-in capital | 1,507,298 | 1,346,996 | ||||||
| Accumulated other comprehensive loss | (44,545 | ) | (43,343 | ) | ||||
| Accumulated deficit | (1,671,979 | ) | (1,521,417 | ) | ||||
| Total Amyris, Inc. stockholders’ deficit | (209,216 | ) | (217,756 | ) | ||||
| Noncontrolling interest | 937 | 937 | ||||||
| Total stockholders' deficit | (208,279 | ) | (216,819 | ) | ||||
| Total liabilities, mezzanine equity and stockholders' deficit | $ | 128,115 | $ | 127,925 | ||||
Amyris, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| (In thousands, except shares and per share amounts) | 2019 | 2018 | 2019 | 2018 | ||||||||||||
| Revenue: | ||||||||||||||||
| Renewable products (includes related party revenue of $0, $13, $2 and $308, respectively) | $ | 17,363 | $ | 9,639 | $ | 41,367 | $ | 21,467 | ||||||||
| Licenses and royalties (includes related party revenue of $0, ($39), $40,302 and $7,366, respectively) | 2,305 | 142 | 43,387 | 7,584 | ||||||||||||
| Grants and collaborations (includes related party revenue of $844, $1,197, $3,886 and $3,667, respectively) | 15,285 | 4,534 | 27,267 | 18,182 | ||||||||||||
| Total revenue (includes related party revenue of $844, $1,171, $44,190 and $11,341, respectively) | 34,953 | 14,315 | 112,021 | 47,233 | ||||||||||||
| Cost and operating expenses: | ||||||||||||||||
| Cost of products sold | 20,654 | 8,574 | 53,482 | 20,423 | ||||||||||||
| Research and development(1) | 19,032 | 16,445 | 56,093 | 49,939 | ||||||||||||
| Sales, general and administrative(1) | 33,341 | 27,239 | 92,456 | 64,793 | ||||||||||||
| Total cost and operating expenses | 73,027 | 52,258 | 202,031 | 135,155 | ||||||||||||
| Loss from operations | (38,074 | ) | (37,943 | ) | (90,010 | ) | (87,922 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Loss on divestiture | - | - | - | (1,778 | ) | |||||||||||
| Interest expense | (12,057 | ) | (9,180 | ) | (39,808 | ) | (28,738 | ) | ||||||||
| Loss from change in fair value of derivative instruments | (398 | ) | (24,797 | ) | (2,437 | ) | (61,164 | ) | ||||||||
| Loss from change in fair value of debt | (2,055 | ) | - | (18,629 | ) | - | ||||||||||
| Loss upon extinguishment of debt | (2,721 | ) | - | (8,596 | ) | (26 | ) | |||||||||
| Other income (expense), net | 1,076 | (2,533 | ) | 920 | (2,009 | ) | ||||||||||
| Total other expense, net | (16,155 | ) | (36,510 | ) | (68,550 | ) | (93,715 | ) | ||||||||
| Loss before income taxes | (54,229 | ) | (74,453 | ) | (158,560 | ) | (181,637 | ) | ||||||||
| Provision for income taxes | (533 | ) | - | (533 | ) | - | ||||||||||
| Net loss attributable to Amyris, Inc. | (54,762 | ) | (74,453 | ) | (159,093 | ) | (181,637 | ) | ||||||||
| Less: deemed dividend to preferred shareholder on issuance and modification of common stock warrants | - | - | (34,964 | ) | - | |||||||||||
| Less: deemed dividend related to proceeds discount and issuance costs upon conversion of Series D preferred stock | - | (6,852 | ) | - | (6,852 | ) | ||||||||||
| Less: losses allocated to participating securities | 1,521 | 4,491 | 6,083 | 12,824 | ||||||||||||
| Net loss attributable to Amyris, Inc. common stockholders | $ | (53,241 | ) | $ | (76,814 | ) | $ | (187,974 | ) | $ | (175,665 | ) | ||||
| Loss per share attributable to common stockholders, basic and diluted | $ | (0.51 | ) | $ | (1.26 | ) | $ | (2.06 | ) | $ | (3.15 | ) | ||||
| Weighted-average shares of common stock outstanding used in computing loss per share of common stock, basic and diluted | 103,449,612 | 60,966,071 | 91,344,150 | 55,735,571 | ||||||||||||
| (1) Includes stock-based compensation expense as follows: | ||||||||||||||||
| Research and development | $ | 663 | $ | 495 | $ | 2,002 | $ | 1,191 | ||||||||
| Sales, general and administrative | 2,571 | 2,442 | 8,058 | 4,924 | ||||||||||||
| $ | 3,234 | $ | 2,937 | $ | 10,060 | $ | 6,115 | |||||||||
Amyris, Inc.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(Unaudited)
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| (In thousands, except per share data) | 2019 | 2018 | 2019 | 2018 | ||||||||||||
| Net loss attributable to Amyris, Inc. common stockholders (GAAP) | $ | (53,241 | ) | $ | (76,814 | ) | $ | (187,974 | ) | $ | (175,665 | ) | ||||
| Non-GAAP adjustments: | ||||||||||||||||
| Stock-based compensation expense | 3,234 | 2,937 | 10,060 | 6,115 | ||||||||||||
| Loss from change in fair value of derivative instruments | 398 | 24,797 | 2,437 | 61,164 | ||||||||||||
| Loss from change in fair value of debt | 2,055 | - | 18,629 | - | ||||||||||||
| Loss upon extinguishment of debt | 2,721 | - | 8,596 | 26 | ||||||||||||
| Deemed dividend to preferred shareholder on issuance and modification of common stock warrants | - | - | 34,964 | - | ||||||||||||
| Deemed dividend related to proceeds discount and issuance costs upon conversion of Series D preferred stock | - | 6,852 | - | 6,852 | ||||||||||||
| Losses allocated to participating securities | (1,521 | ) | (4,491 | ) | (6,083 | ) | (12,824 | ) | ||||||||
| Net loss (income) attributable to Amyris, Inc. common stockholders (non-GAAP) | $ | (46,354 | ) | $ | (46,719 | ) | $ | (119,371 | ) | $ | (114,332 | ) | ||||
| Weighted-average shares outstanding | ||||||||||||||||
| Shares outstanding, basic | 103,449,612 | 60,966,071 | 91,344,150 | 55,735,571 | ||||||||||||
| Net loss per share attributable to Amyris, Inc. common stockholders - Basic (GAAP) | $ | (0.51 | ) | $ | (1.26 | ) | $ | (2.06 | ) | $ | (3.15 | ) | ||||
| Non-GAAP adjustments: | ||||||||||||||||
| Stock-based compensation expense | 0.03 | 0.05 | 0.11 | 0.11 | ||||||||||||
| Loss from change in fair value of derivative instruments | 0.00 | 0.41 | 0.03 | 1.10 | ||||||||||||
| Loss from change in fair value of debt | 0.02 | - | 0.20 | - | ||||||||||||
| Loss upon extinguishment of debt | 0.03 | - | 0.09 | 0.00 | ||||||||||||
| Deemed dividend to preferred shareholder on issuance and modification of common stock warrants | - | - | 0.38 | - | ||||||||||||
| Deemed dividend related to proceeds discount and issuance costs upon conversion of Series D preferred stock | - | 0.11 | - | 0.12 | ||||||||||||
| Losses allocated to participating securities | (0.01 | ) | (0.07 | ) | (0.07 | ) | (0.23 | ) | ||||||||
| Net loss per share attributable to Amyris, Inc. common stockholders - Basic (non-GAAP)(1) | $ | (0.45 | ) | $ | (0.77 | ) | $ | (1.31 | ) | $ | (2.05 | ) | ||||
(1) Amounts may not sum due to rounding.
Amyris, Inc.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(Unaudited)
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| (In thousands) | 2019 | 2018 | 2019 | 2018 | ||||||||||||
| Revenue (GAAP and non-GAAP) | ||||||||||||||||
| Renewable products | $ | 17,363 | $ | 9,639 | $ | 41,367 | $ | 21,467 | ||||||||
| Licenses and royalties | 2,305 | 142 | 43,387 | 7,584 | ||||||||||||
| Grants and collaborations | 15,285 | 4,534 | 27,267 | 18,182 | ||||||||||||
| Total revenue (GAAP and non-GAAP) | $ | 34,953 | $ | 14,315 | $ | 112,021 | $ | 47,233 | ||||||||
| Cost of products sold (GAAP) | $ | 20,654 | $ | 8,574 | $ | 53,482 | $ | 20,423 | ||||||||
| Other costs/provisions | (1,308 | ) | (1,473 | ) | (3,813 | ) | (3,719 | ) | ||||||||
| Excess capacity | (757 | ) | (311 | ) | (1,430 | ) | (1,288 | ) | ||||||||
| Depreciation and amortization | (218 | ) | (126 | ) | (496 | ) | (317 | ) | ||||||||
| Cost of products sold (non-GAAP) | $ | 18,371 | $ | 6,664 | $ | 47,743 | $ | 15,099 | ||||||||
| Adjusted gross profit (non-GAAP)(1) | $ | 16,582 | $ | 7,651 | $ | 64,278 | $ | 32,134 | ||||||||
| Gross margin % | 47 | % | 53 | % | 57 | % | 68 | % | ||||||||
| Research and development expense (GAAP) | $ | 19,032 | $ | 16,445 | $ | 56,093 | $ | 49,939 | ||||||||
| Stock-based compensation expense | (663 | ) | (495 | ) | (2,002 | ) | (1,191 | ) | ||||||||
| Depreciation and amortization | (471 | ) | (552 | ) | (1,341 | ) | (2,916 | ) | ||||||||
| Research and development expense (non-GAAP) | $ | 17,898 | $ | 15,398 | $ | 52,750 | $ | 45,832 | ||||||||
| Sales, general and administrative expense (GAAP) | $ | 33,341 | $ | 27,239 | $ | 92,456 | $ | 64,793 | ||||||||
| Stock-based compensation expense | (2,571 | ) | (2,442 | ) | (8,058 | ) | (4,924 | ) | ||||||||
| Depreciation and amortization | (279 | ) | (336 | ) | (854 | ) | (724 | ) | ||||||||
| Sales, general and administrative expense (non-GAAP) | $ | 30,491 | $ | 24,461 | $ | 83,544 | $ | 59,145 | ||||||||
(1) Non-GAAP Adjusted Gross Profit is calculated based on non-GAAP adjustments to cost of products sold, and does not include costs related to collaborations.